“Congress has an awful habit of talking a really good game on mental health and addiction, but then never being able to meet our rhetoric with resources.” — Sen. Chris Murphy (D-Conn.), speaking at a Senate hearing on the mental health provisions of the 21st Century Cures Act 1 year after the bill’s passage.
“People wondered whether the DOACs are as efficacious as low molecular weight heparins, and both of these trials show that they’re better, which frankly, I was not expecting.” – Alok Khorana, MD, of the Cleveland Clinic, commenting on studies that demonstrated direct oral anticoagulants’ equivalence to low molecular weight heparin for preventing venous thromboembolism in cancer patients.
“We have an FTC and we have a Justice Department. I’m mystified by why we’ve seen no action on any of this.” – Douglas Holtz-Eakin, PhD, president of the American Action Forum, questioning why government agencies don’t scrutinize high prescription drug prices.
“We are getting away from chemotherapy in chronic lymphocytic leukemia; you will probably see multiple [targeted] regimens going forward as people avoid the alkylating agents in these treatments.” — Robert Brodsky, MD, of Johns Hopkins University, discussing new research reported at the ASH annual meeting.
“These products [little cigars and flavored cigars] are not regulated in the same way as cigarettes, and continue to come in flavors that appeal to teens like pina colada. — Robin Koval, president of the anti-tobacco group Truth Initiative, discussing a study showing new lows for cigarette smoking rates among teens in the U.S.
“I can tell you as a physician who’s worked in the system for many, many years, that the emergency room is not a place for people that are experiencing exacerbations of mental health conditions.” — Elinore McCance-Katz, MD, PhD, of the Substance Abuse and Mental Health Services Administration (SAMHSA) and chair of the committee that authored a new report on reforming the nation’s mental health system.
“Prices are set exclusively by drug companies with zero input from anybody else in the supply chain.” — Mark Merritt, of the Pharmaceutical Care Management Association, speaking at a House hearing on the drug supply chain and high drug prices.
“Just giving everybody insulin-sensitizing drugs, there’s no data to support that.” — Andrea Dunaif, MD, of the Icahn School of Medicine at Mount Sinai, on women with PCOS and their diabetes risk.
“Overall, individualized care is the winner here.” — Robert Eckel, MD, of the University of Colorado Denver Anschutz, commenting on personalizing HbA1c targets and the possible implications for healthcare costs.
“Depending on their medical and family histories, long-term hormone therapy should be considered for certain women as the benefits may outweigh the potential harms in certain scenarios.” — Michael Irwig, MD, of the American Association of Clinical Endocrinologists, regarding the USPSTF’s updated hormone therapy recommendation for prevention of chronic disease.
“The cost must be borne by all in a broad, sustainable way.” — Brian Heap, MD, an ob/gyn at McGovern Medical School at UTHealth in Houston, on viability of financial incentives to increase breastfeeding rates